



Autoimmunity and Immune-Dysregulation in Hematological Diseases

Guest Editors:

Dr. Robert Maitta

1. Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
2. University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA

Dr. Xiangrong He

Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

Message from the Guest Editors

The goal of this Special Issue is to examine autoimmunity in hematological disease processes mediated by autoantibody formation and/or immune cell dysfunction. Original submissions describing new developments in the pathophysiology, diagnosis, and therapeutics of hematological diseases with autoimmune components are encouraged. Submissions describing current insights regarding underlying pathophysiological mechanisms, new biologicals or new ways of using existing agents, and reviews are also welcome. Case reports will be considered if the description involves significant novel findings to merit publication or if they include a thorough review of the covered topic.

Deadline for manuscript submissions:

closed (15 August 2023)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)